

Product Data Sheet

Product Name: IL-1R Antagonist

Cat. No.: GC18529

Chemical Properties

Cas. No. 566914-00-9

Chemical Name N-[(1S)-2-methyl-1-(1-pyrrolidinylcarbonyl)propyl]-benzenepropanamide

SMILES O=C(N[C@@H](C(C)C)C(=O)N1CCCC1)CCC2=CC=CC=C2


Formula $C_{18}H_{26}N_2O_2$ M.Wt 302.4

Solubility 10mg/mL in DMSO, or in DMF Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Protocol

Animal experiment [1]:

Animal models Male C57BL6 mice

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Radiotelemetric devices were implanted i.p. into adult male C57BL6 mice 1 week before experiments. The mice recovered in a thermo-neutral room maintained at 31.5°C. The basal temperature recordings were performed for Preparation Method 24h before initiation of experiments. At 10:30 a.m. the day of the experiment, saline or IL-1R Antagonist (TLR1) (diluted in saline; 200mg/kg) was injected i.p. At 10:45 a.m., rmlL-1 β (15 μ g/kg) or saline was injected i.p. The core body temperature was continuously recorded for the following 24h.

Dosage form 200mg/kg; i.p.

Applications IL-1R Antagonist (TLR1) produced a significant attenuation of the IL-1-induced fever response.

References:

[1] Bartfai T, Behrens M M, Gaidarova S, et al. A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses[J]. Proceedings of the National Academy of Sciences, 2003, 100(13): 7971-7976.

Background

IL-1R Antagonist (TLR1) is a peptide that mimics the primary response gene 88 (MyD88) of myeloid differentiation and can alter the interaction between MyD88 and IL-1 receptor type I (IL-1RI)^[1]. Treatment of mouse lymphocytes and thymoma EL4 cells with IL-1R Antagonist ($\geq 10\mu$ M) can inhibit the phosphorylation of IL-1 β -activated p38 MAP kinase, a process specifically mediated by the disruption of IL-1RI/MyD88^[1]. IL-1R Antagonist can block the stress-like effects of IL-1 β in cellular and behavioral models and has the potential to be a new candidate drug for the treatment of depression^[2]. IL-1R Antagonist can effectively inhibit the activation of JNK (c-Jun N-terminal kinase) and NF- κ B (nuclear factor κ B) pathways^[3].

In vivo, IL-1R Antagonist (200mg/kg) administered via intraperitoneal injection to mice with IL-1 β -induced fever significantly reduced the IL-1 β -induced fever response^[1].

References:

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

- [1] Bartfai T, Behrens M M, Gaidarova S, et al. A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses[J]. Proceedings of the National Academy of Sciences, 2003, 100(13): 7971-7976.
- [2] Koo J W, Duman R S. Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depression[J]. Current opinion in investigational drugs (London, England: 2000), 2009, 10(7): 664.
- [3] Loiarro M, Ruggiero V, Sette C. Targeting TLR/IL-1R signalling in human diseases[J]. Mediators of inflammation, 2010, 2010(1): 674363.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA